325 related articles for article (PubMed ID: 11170509)
1. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.
Tettey JN; Maggs JL; Rapeport WG; Pirmohamed M; Park BK
Chem Res Toxicol; 2001 Aug; 14(8):965-74. PubMed ID: 11511170
[TBL] [Abstract][Full Text] [Related]
3. Identification of glutathione conjugates of troglitazone in human hepatocytes.
Prabhu S; Fackett A; Lloyd S; McClellan HA; Terrell CM; Silber PM; Li AP
Chem Biol Interact; 2002 Nov; 142(1-2):83-97. PubMed ID: 12399157
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.
Yamazaki H; Shibata A; Suzuki M; Nakajima M; Shimada N; Guengerich FP; Yokoi T
Drug Metab Dispos; 1999 Nov; 27(11):1260-6. PubMed ID: 10534310
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
Alvarez-Sanchez R; Montavon F; Hartung T; Pähler A
Chem Res Toxicol; 2006 Aug; 19(8):1106-16. PubMed ID: 16918252
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
[TBL] [Abstract][Full Text] [Related]
8. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone.
Okada R; Maeda K; Nishiyama T; Aoyama S; Tozuka Z; Hiratsuka A; Ikeda T; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2011 Dec; 39(12):2290-7. PubMed ID: 21914835
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols.
Reddy VB; Karanam BV; Gruber WL; Wallace MA; Vincent SH; Franklin RB; Baillie TA
Chem Res Toxicol; 2005 May; 18(5):880-8. PubMed ID: 15892582
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction.
He K; Woolf TF; Kindt EK; Fielder AE; Talaat RE
Biochem Pharmacol; 2001 Jul; 62(2):191-8. PubMed ID: 11389877
[TBL] [Abstract][Full Text] [Related]
12. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
13. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells.
Yamamoto Y; Yamazaki H; Ikeda T; Watanabe T; Iwabuchi H; Nakajima M; Yokoi T
Drug Metab Dispos; 2002 Feb; 30(2):155-60. PubMed ID: 11792684
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption and excretion of troglitazone sulphate, a major biliary metabolite of troglitazone.
Kawai K; Hirota T; Muramatsu S; Tsuruta F; Ikeda T; Kobashi K; Nakamura KI
Xenobiotica; 2000 Jul; 30(7):707-15. PubMed ID: 10963061
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
[TBL] [Abstract][Full Text] [Related]
16. Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.
Madsen KG; Grönberg G; Skonberg C; Jurva U; Hansen SH; Olsen J
Chem Res Toxicol; 2008 Oct; 21(10):2035-41. PubMed ID: 18788755
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Masubuchi Y
Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
[TBL] [Abstract][Full Text] [Related]
18. Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR.
Chen H; Shockcor J; Chen W; Espina R; Gan LS; Mutlib AE
Chem Res Toxicol; 2002 Mar; 15(3):388-99. PubMed ID: 11896687
[TBL] [Abstract][Full Text] [Related]
19. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes.
Hewitt NJ; Lloyd S; Hayden M; Butler R; Sakai Y; Springer R; Fackett A; Li AP
Chem Biol Interact; 2002 Nov; 142(1-2):73-82. PubMed ID: 12399156
[TBL] [Abstract][Full Text] [Related]
20. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk C; Ponelle C; Scheuermann G; Pantze M
Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
